NASDAQ:ALNY Alnylam Pharmaceuticals (ALNY) Stock Price, News & Analysis → top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (From Traders Agency) (Ad) Free ALNY Stock Alerts $145.79 +1.38 (+0.96%) (As of 04/22/2024 ET) Add Compare Share Share Today's Range$143.69▼$147.8650-Day Range$144.41▼$164.1552-Week Range$143.50▼$218.88Volume399,984 shsAverage Volume792,052 shsMarket Capitalization$18.36 billionP/E RatioN/ADividend YieldN/APrice Target$216.12 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Alnylam Pharmaceuticals alerts: Email Address Alnylam Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.56 Rating ScoreUpside/Downside48.2% Upside$216.12 Price TargetShort InterestHealthy2.22% of Shares Sold ShortDividend StrengthN/ASustainability-1.52Upright™ Environmental ScoreNews Sentiment0.12Based on 9 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($4.54) to ($2.22) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.35 out of 5 starsMedical Sector114th out of 909 stocksPharmaceutical Preparations Industry38th out of 426 stocks 4.3 Analyst's Opinion Consensus RatingAlnylam Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.56, and is based on 10 buy ratings, 8 hold ratings, and no sell ratings.Amount of Analyst CoverageAlnylam Pharmaceuticals has been the subject of 13 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 3.0 Short Interest Percentage of Shares Shorted2.22% of the outstanding shares of Alnylam Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverAlnylam Pharmaceuticals has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Alnylam Pharmaceuticals has recently increased by 4.09%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldAlnylam Pharmaceuticals does not currently pay a dividend.Dividend GrowthAlnylam Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.3 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAlnylam Pharmaceuticals has received a 63.92% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Gene therapy medication", "Clinical research services", and "Preclinical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Alnylam Pharmaceuticals is -1.52. Previous Next 1.7 News and Social Media Coverage News SentimentAlnylam Pharmaceuticals has a news sentiment score of 0.12. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.49 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Alnylam Pharmaceuticals this week, compared to 8 articles on an average week.Search InterestOnly 9 people have searched for ALNY on MarketBeat in the last 30 days. This is a decrease of -18% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Alnylam Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Alnylam Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.50% of the stock of Alnylam Pharmaceuticals is held by insiders.Percentage Held by Institutions92.97% of the stock of Alnylam Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Alnylam Pharmaceuticals are expected to grow in the coming year, from ($4.54) to ($2.22) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Alnylam Pharmaceuticals is -40.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Alnylam Pharmaceuticals is -40.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Traders Agencytop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution… About Alnylam Pharmaceuticals Stock (NASDAQ:ALNY)Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.Read More ALNY Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ALNY Stock News HeadlinesApril 21, 2024 | americanbankingnews.comAlnylam Pharmaceuticals (NASDAQ:ALNY) Hits New 12-Month Low at $143.50April 21, 2024 | americanbankingnews.comStockNews.com Downgrades Alnylam Pharmaceuticals (NASDAQ:ALNY) to HoldApril 23, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.April 19, 2024 | benzinga.comHow Is The Market Feeling About Alnylam Pharmaceuticals?April 18, 2024 | businesswire.comAlnylam to Webcast Conference Call Discussing First Quarter 2024 Financial ResultsApril 17, 2024 | stocknews.com3 Biotech Stocks Paving the Way for Bullish Investment GainsApril 17, 2024 | markets.businessinsider.comLevi & Korsinsky Reminds Alnylam Investors of the Ongoing Investigation into Potential Violations of Securities Laws - ALNYApril 13, 2024 | americanbankingnews.comAlnylam Pharmaceuticals (NASDAQ:ALNY) Upgraded to Buy by StockNews.comApril 23, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.April 13, 2024 | americanbankingnews.comZacks Research Comments on Alnylam Pharmaceuticals, Inc.'s Q1 2024 Earnings (NASDAQ:ALNY)April 11, 2024 | benzinga.comRegeneron Pharmaceuticals's Options: A Look at What the Big Money is ThinkingApril 9, 2024 | markets.businessinsider.comBuy Rating Affirmed for Alnylam Pharma on Strong Zilebesiran Trial Results and Lucrative Roche PartnershipApril 8, 2024 | msn.comWegovy Helps HFpEF Patients With Diabetes MellitusApril 8, 2024 | msn.comStudy shows promise of zilebesiran injection in reducing systolic blood pressureApril 8, 2024 | markets.businessinsider.comJefferies Keeps Their Buy Rating on Alnylam Pharma (ALNY)April 7, 2024 | markets.businessinsider.comAlnylam Presents Positive Results From KARDIA-2 Phase 2 Study Of Zilebesiran At ACCApril 7, 2024 | businesswire.comAlnylam Presents Positive Results from the KARDIA-2 Phase 2 Study of Zilebesiran Added to Standard of Care Antihypertensives in Patients with Inadequately Controlled HypertensionApril 6, 2024 | finance.yahoo.comThose who invested in Alnylam Pharmaceuticals (NASDAQ:ALNY) five years ago are up 63%April 5, 2024 | bizjournals.comAlnylam CEO’s total pay nearly doubles, hitting $8.9MApril 3, 2024 | markets.businessinsider.comPiper Sandler Keeps Their Buy Rating on Sutro Biopharma (STRO)April 3, 2024 | markets.businessinsider.comPiper Sandler Keeps Their Buy Rating on Aptose Biosciences (APTO)April 2, 2024 | benzinga.com$100 Invested In Alnylam Pharmaceuticals 15 Years Ago Would Be Worth This Much TodayMarch 26, 2024 | markets.businessinsider.comDecoding 12 Analyst Evaluations For Regeneron PharmaceuticalsMarch 25, 2024 | markets.businessinsider.comBuy Rating Affirmed for Alnylam Pharmaceuticals on Strong Commercial Business and Expanding CNS PipelineMarch 20, 2024 | businesswire.comAlnylam to Webcast Investor Event to Discuss Results from KARDIA-2 Phase 2 Study of Zilebesiran at American College of Cardiology Scientific SessionMarch 19, 2024 | finance.yahoo.comRapport Therapeutics Appoints Pioneering Industry Leader John Maraganore to Board of DirectorsMarch 19, 2024 | markets.businessinsider.comTD Cowen Keeps Their Buy Rating on Tenaya Therapeutics (TNYA)See More Headlines Receive ALNY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Alnylam Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/15/2024Today4/22/2024Next Earnings (Confirmed)5/02/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:ALNY CUSIP02043Q10 CIK1178670 Webwww.alnylam.com Phone(617) 551-8200Fax617-551-8101Employees2,100Year Founded2002Price Target and Rating Average Stock Price Target$216.12 High Stock Price Target$395.00 Low Stock Price Target$161.00 Potential Upside/Downside+48.2%Consensus RatingModerate Buy Rating Score (0-4)2.56 Research Coverage18 Analysts Profitability EPS (Most Recent Fiscal Year)($3.56) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-440,240,000.00 Net Margins-24.08% Pretax Margin-23.71% Return on EquityN/A Return on Assets-12.18% Debt Debt-to-Equity RatioN/A Current Ratio3.08 Quick Ratio2.99 Sales & Book Value Annual Sales$1.83 billion Price / Sales10.04 Cash FlowN/A Price / Cash FlowN/A Book Value($1.76) per share Price / Book-82.84Miscellaneous Outstanding Shares125,950,000Free Float124,057,000Market Cap$18.36 billion OptionableOptionable Beta0.39 Social Links 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesDr. Yvonne L. Greenstreet M.B.A. (Age 61)MBChB, CEO & Director Comp: $2.15MMr. Jeffrey V. Poulton M.B.A. (Age 56)CFO & Executive VP Comp: $1.05MDr. Akshay K. Vaishnaw M.D. (Age 61)Ph.D., Chief Innovation Officer & Member of the Scientific Advisory Board Comp: $1.12MDr. Pushkal P. Garg M.D. (Age 56)Chief Medical Officer and Executive VP of Development & Medical Affairs Comp: $1.06MMr. Tolga Tanguler M.B.A. (Age 51)Executive VP & Chief Commercial Officer Comp: $971.3kMr. Timothy J. MainesChief Technical Operations & Quality OfficerDr. Kevin Joseph Fitzgerald Ph.D. (Age 55)Senior VP, Head of Research & Chief Scientific Officer Ms. Christine Regan Lindenboom (Age 43)Senior VP of Investor Relations & Corporate Communications Mr. Piyush Sharma J.D.Chief Ethics & Compliance OfficerMr. Evan Lippman M.B.A.Chief Corporate Development & Strategy OfficerMore ExecutivesKey CompetitorsBioMarin PharmaceuticalNASDAQ:BMRNRoyalty PharmaNASDAQ:RPRXMyoKardiaNASDAQ:MYOKUnited TherapeuticsNASDAQ:UTHRHorizon Therapeutics PublicNASDAQ:HZNPView All CompetitorsInsiders & InstitutionsIFM Investors Pty LtdBought 780 shares on 4/22/2024Ownership: 0.020%EFG Asset Management Americas Corp.Sold 5,365 shares on 4/22/2024Ownership: 0.009%GraniteShares Advisors LLCBought 387 shares on 4/22/2024Ownership: 0.003%Maryland State Retirement & Pension SystemBought 385 shares on 4/20/2024Ownership: 0.008%First Trust Direct Indexing L.P.Sold 242 shares on 4/19/2024Ownership: 0.002%View All Insider TransactionsView All Institutional Transactions Should I Buy Alnylam Pharmaceuticals Stock? ALNY Pros and Cons Explained Pros Here are some ways that investors could benefit from investing in Alnylam Pharmaceuticals, Inc.: Alnylam Pharmaceuticals has a diverse portfolio of innovative therapeutics based on ribonucleic acid interference, including successful products like ONPATTRO, AMVUTTRA, GIVLAARI, and OXLUMO, targeting various rare diseases. The company has shown consistent revenue growth, with a 31.2% increase in revenue year-over-year, indicating a strong market presence and potential for further expansion. Recent earnings reports have shown positive results, with the company beating consensus estimates and demonstrating resilience in challenging market conditions. Institutional investors have been increasing their stakes in Alnylam Pharmaceuticals, signaling confidence in the company's future prospects and growth potential. Alnylam Pharmaceuticals' stock has a low beta of 0.39, indicating lower volatility compared to the market, which can be attractive to risk-averse investors. Cons Investors should be bearish about investing in Alnylam Pharmaceuticals, Inc. for these reasons: The biopharmaceutical industry is highly competitive and subject to regulatory challenges, which could impact the company's ability to bring new products to market and maintain profitability. Alnylam Pharmaceuticals' stock price may be influenced by factors such as clinical trial results, regulatory approvals, and market sentiment, leading to potential short-term volatility. Investing in biotechnology companies like Alnylam Pharmaceuticals carries inherent risks related to product development, clinical trial outcomes, and market acceptance, which can lead to significant fluctuations in stock value. The company's future success heavily relies on the continued innovation and commercialization of its pipeline products, which may face delays or setbacks in development, impacting financial performance. Market conditions and macroeconomic factors can also affect the biopharmaceutical sector, potentially impacting Alnylam Pharmaceuticals' stock performance and overall investor returns. These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Friday, April 12, 2024. Please send any questions or comments about these Alnylam Pharmaceuticals pros and cons to contact@marketbeat.com. ALNY Stock Analysis - Frequently Asked Questions Should I buy or sell Alnylam Pharmaceuticals stock right now? 18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alnylam Pharmaceuticals in the last year. There are currently 8 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" ALNY shares. View ALNY analyst ratings or view top-rated stocks. What is Alnylam Pharmaceuticals' stock price target for 2024? 18 Wall Street research analysts have issued twelve-month price targets for Alnylam Pharmaceuticals' stock. Their ALNY share price targets range from $161.00 to $395.00. On average, they anticipate the company's share price to reach $216.12 in the next twelve months. This suggests a possible upside of 48.2% from the stock's current price. View analysts price targets for ALNY or view top-rated stocks among Wall Street analysts. How have ALNY shares performed in 2024? Alnylam Pharmaceuticals' stock was trading at $191.41 at the start of the year. Since then, ALNY shares have decreased by 23.8% and is now trading at $145.79. View the best growth stocks for 2024 here. When is Alnylam Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our ALNY earnings forecast. How can I listen to Alnylam Pharmaceuticals' earnings call? Alnylam Pharmaceuticals will be holding an earnings conference call on Thursday, May 2nd at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link. How were Alnylam Pharmaceuticals' earnings last quarter? Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) announced its quarterly earnings results on Thursday, February, 15th. The biopharmaceutical company reported ($1.10) earnings per share for the quarter, beating analysts' consensus estimates of ($1.20) by $0.10. The biopharmaceutical company had revenue of $439.72 million for the quarter, compared to analyst estimates of $439.38 million. The business's quarterly revenue was up 31.2% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($1.68) earnings per share. What ETFs hold Alnylam Pharmaceuticals' stock? ETFs with the largest weight of Alnylam Pharmaceuticals (NASDAQ:ALNY) stock in their portfolio include Morningstar US Small Growth (MSGR), Amplify Treatments, Testing and Advancements ETF (GERM), Global X Genomics & Biotechnology ETF (GNOM), Principal Healthcare Innovators ETF (BTEC), First Trust NYSE Arca Biotechnology Index Fund (FBT), Horizon Kinetics Medical ETF (MEDX), American CenturyFocused Dynamic Growth ETF (FDG) and Fidelity Disruptive Medicine ETF (FMED). What guidance has Alnylam Pharmaceuticals issued on next quarter's earnings? Alnylam Pharmaceuticals issued an update on its FY 2024 earnings guidance on Friday, February, 16th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $1.7 billion-$1.9 billion, compared to the consensus revenue estimate of $1.8 billion. What is John M. Maraganore's approval rating as Alnylam Pharmaceuticals' CEO? 65 employees have rated Alnylam Pharmaceuticals Chief Executive Officer John M. Maraganore on Glassdoor.com. John M. Maraganore has an approval rating of 99% among the company's employees. This puts John M. Maraganore in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Alnylam Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Alnylam Pharmaceuticals investors own include Alibaba Group (BABA), NVIDIA (NVDA), XOMA (XOMA), Ionis Pharmaceuticals (IONS), Gilead Sciences (GILD), NXP Semiconductors (NXPI), Mylan (MYL), AbbVie (ABBV), Micron Technology (MU) and Advanced Micro Devices (AMD). Who are Alnylam Pharmaceuticals' major shareholders? Alnylam Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include Sumitomo Mitsui Trust Holdings Inc. (0.23%), Portman Square Capital LLP (0.00%), IFM Investors Pty Ltd (0.02%), EFG Asset Management Americas Corp. (0.01%), Maryland State Retirement & Pension System (0.01%) and SteelPeak Wealth LLC (0.01%). Insiders that own company stock include Akshay Vaishnaw, Indrani Lall Franchini, Jeffrey V Poulton, Jeffrey W Dunn, John Maraganore, Laurie Keating, Michael W Bonney, Pushkal Garg, Steven M Paul, Tolga Tanguler and Yvonne Greenstreet. View institutional ownership trends. How do I buy shares of Alnylam Pharmaceuticals? Shares of ALNY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ALNY) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingHealthcare Takes A Big Step Forward With The Help Of AIThe Bull Reporttop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap Profits[Shocking] Elon Musk’s Plan To End BanksCrypto 101 MediaForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressMan Who Predicted 2008: “This Will be Worse.”AltimetryThe #1 Crypto for 2024InvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alnylam Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.